Agios Records 44 PYRUKYND Scripts, Eyes $1B Market and 2026 Catalysts
Agios Pharmaceuticals recorded 44 PYRUKYND prescriptions in its first 4–5 weeks, targeting ~4,000 U.S. thalassemia patients from a 6,000-patient pool and forecasting a $1 billion global market. It unveiled 2026 catalysts: H1 Phase 2b MDS readout, H2 sickle cell top-line data and Q1 pre-sNDA meeting; mitapivat met hemoglobin but not VOC endpoints.
1. PYRUKYND Early Launch Traction
Agios reported 44 PYRUKYND prescriptions in its first four to five launch weeks and estimates about 6,000 diagnosed U.S. adult thalassemia patients. The company sees an initial addressable segment of ~4,000 split evenly between transfusion-dependent and non-dependent groups, projects a $1 billion global market and expects payer formulary placement to take six to nine months before gradual uptake.
2. 2026 Pipeline Catalysts
The 2026 catalyst calendar includes a H1 Phase 2b tebapivat readout in lower-risk myelodysplastic syndrome, H2 top-line sickle cell data for tebapivat and mitapivat, and Phase 1 healthy-volunteer results for AG-236 TMPRSS6 siRNA.
3. Hemoglobin Endpoint Success and Regulatory Pathway
In RISE UP Phase 3 sickle cell disease, mitapivat met the hemoglobin endpoint with 41% of patients achieving ≥1 g/dL improvement and favorable safety, but did not achieve significant reduction in vaso-occlusive crises. Agios plans a Q1 pre-sNDA FDA meeting to outline its regulatory strategy and will disclose details upon receiving meeting minutes.